ID

11988

Descrizione

Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL); ODM derived from: https://clinicaltrials.gov/show/NCT02192021

collegamento

https://clinicaltrials.gov/show/NCT02192021

Keywords

versioni (1)
  1. 30/08/15 30/08/15 -
Titolare del copyright

ODM derived from: https://clinicaltrials.gov/show/NCT02192021

Caricato su

30 agosto 2015

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility ´T Cell Lymphoma NCT02192021

Inglese

Eligibility Cutaneous T Cell Lymphoma NCT02192021

1 moduli  
Inclusion Criteria
Descrizione

Inclusion Criteria

diagnosis of cutaneous t-cell lymphoma (ctcl) based upon a skin biopsy diagnostic of atypical epidermotropism of folliculocentric or epidermotropic t-cells.
Descrizione

t-cell lymphoma; diagnosis; cutaneous; biopsy; skin

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0079773
current stage of ia or ib.
Descrizione

t stage; current

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0677955
expected survival of greater than or equal to12 months.
Descrizione

no code found

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0038952
not be on any other investigational device/drug treatment.
Descrizione

treatment; other; device; drug

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C2346570
UMLS CUI [1,2]
C0013230
have a sufficient number (i.e., n=4 for first dose cohort in initial safety evaluation; n=3 for remainder of subjects) and surface area (> 5 cm2) of ctcl patches or plaques for micro needle array-doxorubicin (mna-d) and micro needle array (mna) application.
Descrizione

application; doxorubicin; initial; number; cohort; first; dose; area

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0013089
willing to adhere to the instructions of the investigator and his research team and sign an informed consent form prior to entry into the study.
Descrizione

informed consent; investigator; entry; study

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0021430
have the following initial and subsequent pretreatment laboratory parameters: granulocytes ≥2,000/mm3; platelets >50,000/mm3; Serum creatinine level ≤2x the upper limit of normal (uln); ast, alt, , ldh, alk phos ≤3x the uln.subjects must be ³ 18 years of age and must be able to understand the written informed consent/assent document.
Descrizione

upper limit of normal (sgpt); upper limit of normal (sgot); >= 18 years of age; informed consent; < 18 years of age; > 18 years of age; serum creatinine; granulocytes; platelets; laboratory; initial; ldh; ast; uln; alt

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0018183
UMLS CUI [2]
C0005821
UMLS CUI [3]
C0600061
UMLS CUI [4]
C0438236
have no evidence of active infection, regardless of the degree of severity or localization. subjects with active infections (whether or not they require antibiotic therapy) may be eligible for study participation after complete resolution of the infection. subjects on antibiotic therapy must be off antibiotics before beginning treatment.
Descrizione

antibiotic therapy; active infections; evidence of; treatment; severity; complete; degree; study

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0009450
not receive any other treatment for ctcl except emollients of subject's choice without topical steroids, anti-fungal or antibacterial topical preparations.
Descrizione

other treatment; anti-fungal; steroids; topical

Tipo di dati

boolean

Alias
UMLS CUI [1]
C2015819
willing to discontinue concomitant medications for ctcl for the duration of their study participation, including: high dose topical steroids - 2 week washout; oral steroids above 10 mg - 3 week washout; psoralen + ultraviolet a light (puva) or ultraviolet b light (uvb) (including sunbathing, tanning beds, etc.) - 2 week washout; extracorporeal photopheresis - 2 week washout; electron beam - 2 weeks washout; chemotherapeutic agents - 3 week washout; bexarotene capsules or other oral biologics - 2 week washout; and topical nitrogen mustard - 2 week washout.
Descrizione

concomitant medications; chemotherapeutic agent; steroids; duration; capsules; electron; topical; agents; study; dose; high; oral; puva; week

Tipo di dati

boolean

Alias
UMLS CUI [1]
C2347852
Exclusion Criteria
Descrizione

Exclusion Criteria

Exclusion Criteria
Descrizione

Exclusion Criteria

uncontrolled pain.
Descrizione

pain

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1557623
known history of autoimmune disease; or active hiv, htlv-1, and/or hepatitis infection.
Descrizione

autoimmune disease; infection; hepatitis; active; hiv

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0004364
UMLS CUI [2]
C0019158
UMLS CUI [3]
C0019682
pregnant or lactating.
Descrizione

pregnant

Tipo di dati

boolean

Alias
UMLS CUI [1]
C2828358
UMLS CUI [2]
C0549206
have sensitivity to drugs that provide local anesthesia.
Descrizione

local anesthesia; drugs

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0237865
have active malignancies with the exception of non-metastatic prostate cancer and carcinoma in situ of the skin and cervix.
Descrizione

carcinoma in situ; metastatic; prostate; exception; cervix; active; cancer; skin; non

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0006826
Ritorna all'inizio della pagina

Similar models

Eligibility Cutaneous T Cell Lymphoma NCT02192021

1 moduli
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
t-cell lymphoma; diagnosis; cutaneous; biopsy; skin
Item
diagnosis of cutaneous t-cell lymphoma (ctcl) based upon a skin biopsy diagnostic of atypical epidermotropism of folliculocentric or epidermotropic t-cells.
boolean
C0079773 (UMLS CUI [1])
t stage; current
Item
current stage of ia or ib.
boolean
C0677955 (UMLS CUI [1])
no code found
Item
expected survival of greater than or equal to12 months.
boolean
C0038952 (UMLS CUI [1])
treatment; other; device; drug
Item
not be on any other investigational device/drug treatment.
boolean
C2346570 (UMLS CUI [1,1])
C0013230 (UMLS CUI [1,2])
application; doxorubicin; initial; number; cohort; first; dose; area
Item
have a sufficient number (i.e., n=4 for first dose cohort in initial safety evaluation; n=3 for remainder of subjects) and surface area (> 5 cm2) of ctcl patches or plaques for micro needle array-doxorubicin (mna-d) and micro needle array (mna) application.
boolean
C0013089 (UMLS CUI [1])
informed consent; investigator; entry; study
Item
willing to adhere to the instructions of the investigator and his research team and sign an informed consent form prior to entry into the study.
boolean
C0021430 (UMLS CUI [1])
upper limit of normal (sgpt); upper limit of normal (sgot); >= 18 years of age; informed consent; < 18 years of age; > 18 years of age; serum creatinine; granulocytes; platelets; laboratory; initial; ldh; ast; uln; alt
Item
have the following initial and subsequent pretreatment laboratory parameters: granulocytes ≥2,000/mm3; platelets >50,000/mm3; Serum creatinine level ≤2x the upper limit of normal (uln); ast, alt, , ldh, alk phos ≤3x the uln.subjects must be ³ 18 years of age and must be able to understand the written informed consent/assent document.
boolean
C0018183 (UMLS CUI [1])
C0005821 (UMLS CUI [2])
C0600061 (UMLS CUI [3])
C0438236 (UMLS CUI [4])
antibiotic therapy; active infections; evidence of; treatment; severity; complete; degree; study
Item
have no evidence of active infection, regardless of the degree of severity or localization. subjects with active infections (whether or not they require antibiotic therapy) may be eligible for study participation after complete resolution of the infection. subjects on antibiotic therapy must be off antibiotics before beginning treatment.
boolean
C0009450 (UMLS CUI [1])
other treatment; anti-fungal; steroids; topical
Item
not receive any other treatment for ctcl except emollients of subject's choice without topical steroids, anti-fungal or antibacterial topical preparations.
boolean
C2015819 (UMLS CUI [1])
concomitant medications; chemotherapeutic agent; steroids; duration; capsules; electron; topical; agents; study; dose; high; oral; puva; week
Item
willing to discontinue concomitant medications for ctcl for the duration of their study participation, including: high dose topical steroids - 2 week washout; oral steroids above 10 mg - 3 week washout; psoralen + ultraviolet a light (puva) or ultraviolet b light (uvb) (including sunbathing, tanning beds, etc.) - 2 week washout; extracorporeal photopheresis - 2 week washout; electron beam - 2 weeks washout; chemotherapeutic agents - 3 week washout; bexarotene capsules or other oral biologics - 2 week washout; and topical nitrogen mustard - 2 week washout.
boolean
C2347852 (UMLS CUI [1])
pain
Item
uncontrolled pain.
boolean
C1557623 (UMLS CUI [1])
autoimmune disease; infection; hepatitis; active; hiv
Item
known history of autoimmune disease; or active hiv, htlv-1, and/or hepatitis infection.
boolean
C0004364 (UMLS CUI [1])
C0019158 (UMLS CUI [2])
C0019682 (UMLS CUI [3])
pregnant
Item
pregnant or lactating.
boolean
C2828358 (UMLS CUI [1])
C0549206 (UMLS CUI [2])
local anesthesia; drugs
Item
have sensitivity to drugs that provide local anesthesia.
boolean
C0237865 (UMLS CUI [1])
carcinoma in situ; metastatic; prostate; exception; cervix; active; cancer; skin; non
Item
have active malignancies with the exception of non-metastatic prostate cancer and carcinoma in situ of the skin and cervix.
boolean
C0006826 (UMLS CUI [1])
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial